Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

CRISPR-engineered T cells in patients with refractory cancer.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.

Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print]

PMID:
32029687
2.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

3.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

4.

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies.

Stadtmauer E, Mangan PA.

J Adv Pract Oncol. 2017 Apr;8(3):228-231. Epub 2017 Apr 1. Review.

5.

Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA.

Lancet Haematol. 2015 Oct;2(10):e408-16. doi: 10.1016/S2352-3026(15)00151-9. Epub 2015 Sep 17.

PMID:
26686042
6.

Autologous hematopoietic stem cell transplantation for multiple myeloma: frequently asked questions.

Mangan PA, Gleason CL, Miceli T.

Clin J Oncol Nurs. 2013 Dec;17 Suppl:43-7. doi: 10.1188/13.CJON.43-47.

7.

Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice.

Miceli T, Lilleby K, Noonan K, Kurtin S, Faiman B, Mangan PA.

Clin J Oncol Nurs. 2013 Dec;17 Suppl:13-24. doi: 10.1188/13.CJON.S2.13-24. Review.

8.

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE.

Blood. 2011 Jan 6;117(1):63-71. doi: 10.1182/blood-2010-07-296822. Epub 2010 Sep 23.

9.

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.

Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K, Cunningham K, Luger SM, Porter DL, Schuster S, O'Doherty U, Siegel D, Stadtmauer EA.

Bone Marrow Transplant. 2011 Jan;46(1):59-63. doi: 10.1038/bmt.2010.63. Epub 2010 May 3.

PMID:
20421869
10.

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA.

Bone Marrow Transplant. 2009 Mar;43(5):417-22. doi: 10.1038/bmt.2008.334. Epub 2008 Oct 13.

11.

Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Faiman B, Bilotti E, Mangan PA, Rogers K; IMF Nurse Leadership Board.

Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):53-63. doi: 10.1188/08.CJON.S1.53-62.

12.

Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.

Bertolotti P, Bilotti E, Colson K, Curran K, Doss D, Faiman B, Gavino M, Jenkins B, Lilleby K, Love G, Mangan PA, McCullagh E, Miceli T, Miller K, Rogers K, Rome S, Sandifer S, Smith LC, Tariman JD, Westphal J.

Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):9-12. doi: 10.1188/08.CJON.S1.9-12.

13.

Impact of EmbryoGlue as the embryo transfer medium.

Hazlett WD, Meyer LR, Nasta TE, Mangan PA, Karande VC.

Fertil Steril. 2008 Jul;90(1):214-6. Epub 2007 Sep 4.

PMID:
17765233
14.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

15.

Caregiving at the end of life: Perceptions of health care quality and quality of life among patients and caregivers.

Fleming DA, Sheppard VB, Mangan PA, Taylor KL, Tallarico M, Adams I, Ingham J.

J Pain Symptom Manage. 2006 May;31(5):407-20.

16.

Caregiving near the end of life: unmet needs and potential solutions.

Mangan PA, Taylor KL, Yabroff KR, Fleming DA, Ingham JM.

Palliat Support Care. 2003 Sep;1(3):247-59.

PMID:
16594425
17.

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.

Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA.

Bone Marrow Transplant. 2005 Dec;36(11):955-61.

PMID:
16205727
18.

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA.

Bone Marrow Transplant. 2002 Jul;30(1):23-8.

19.

Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.

Stadtmauer EA, Tsai DE, Sickles CJ, Mick R, Luger SM, Porter DL, Mangan PA, Schuchter LM, Schuster SJ, Loh EY, Magee DA, Sachs RA, Wall ME, Moore J, Buzby GP, Zaleta E, Kamoun M, Silberstein LE.

Med Oncol. 1999 Dec;16(4):279-88.

PMID:
10618691
20.

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.

Moore HC, Mick R, Solin LJ, Sickles C, Mangan PA, Luger SM, Fox KR, Schuchter LM, Loh E, Porter DL, Schuster S, Buzby GP, Glatstein E, Silberstein LE, Stadtmauer EA.

Ann Oncol. 1999 Aug;10(8):929-36.

21.

Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.

Morgan MA, Stadtmauer EA, Luger SM, Porter DL, Mangan PA, O'Neil P, Kamelle S, Benjamin I, Mick R, King SA, Rubin SC.

Gynecol Oncol. 1997 Dec;67(3):272-6.

PMID:
9441774

Supplemental Content

Loading ...
Support Center